LEADER 03825nam  22005775  450 
001 9910337952803321
005 20200704114111.0
010   $a3-030-17864-1
024 7 $a10.1007/978-3-030-17864-2
035   $a(CKB)4100000008339108
035   $a(MiAaPQ)EBC5780778
035   $a(DE-He213)978-3-030-17864-2
035   $a(PPN)236519921
035   $a(EXLCZ)994100000008339108
100   $a20190528d2019      u|             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aMHC Class-I Loss and Cancer Immune Escape$b[electronic resource] /$fby Federico Garrido
205   $a1st ed. 2019.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019.
215   $a1 online resource (109 pages) $cillustrations
225 1 $aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v1151
311   $a3-030-17863-3 
327   $aPreface -- Introduction -- Mhc/Hla Class I Loss In Cancer Cells -- Hla Class-I Expression And Cancer Immunotherapy -- Hla Class-Ii Expression In Human Tumors -- Index.
330   $aThis book is about the escape strategies used by cancer cells to avoid the immune response of the host. The main characters of this story are the ?Antigen Presenting Molecules? and the ?T Lymphocytes?. The former are known as the Major Histocompatibility Complex (MHC): the H-2 and the HLA molecules. The latter are a subgroup of white cells travelling all over our body which are capable to distinguish between ?self and non self?. Readers will know from the inside about the history of the HLA genetic system and will discover how T lymphocytes recognize and destroy cancer cells. One of the key important questions is: Why tumors arise, develop and metastasize? This book tries to answer this question and will explain how cancer cells become invisible to killer T lymphocytes. The loss of the HLA molecules is a major player in this tumor escape mechanism. Cancer immunotherapy is aimed at stimulating T lymphocytes to destroy tumor cells. However, the clinical response rate is not as high as expected. The molecular mechanisms responsible for MHC/HLA antigen loss play a crucial role in this resistance to immunotherapy. This immune escape mechanism will be discussed in different types of tumors: lung, prostate, bladder and breast?ect. as well as melanoma and lymphoma. This book will be useful to Oncologists, Pathologists and Immunologist that will enter this fascinating area of research. It will be also interesting for biologist, doctoral students and medical residents interested in ?Tumor Immunology?. .
410  0$aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v1151
606   $aCancer research
606   $aMolecular biology
606   $aImmunology
606   $aHuman genetics
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
606   $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X
606   $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000
606   $aHuman Genetics$3https://scigraph.springernature.com/ontologies/product-market-codes/B12008
615  0$aCancer research.
615  0$aMolecular biology.
615  0$aImmunology.
615  0$aHuman genetics.
615 14$aCancer Research.
615 24$aMolecular Medicine.
615 24$aImmunology.
615 24$aHuman Genetics.
676   $a616.994079
700   $aGarrido$b Federico$4aut$4http://id.loc.gov/vocabulary/relators/aut$0995416
906   $aBOOK
912   $a9910337952803321
996   $aMHC Class-I Loss and Cancer Immune Escape$92280543
997   $aUNINA